StatPearls, LLC

  • Diabetes Mellitus, Type 2
  • Glucagon-Like Peptide-1 Receptor Agonists
  • Insulin
  • Liraglutide
  • Obesity

Liraglutide

Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) used to treat type 2 diabetes (T2D) and obesity. This drug belongs to the incretin mimetic class of antidiabetic agents and acts on pancreatic -cells to stimulate the release of endogenous insulin, helping to control blood glucose levels and suppress appetite. The FDA approved liraglutide in 2010 as a treatment for T2D and in 2014 for weight loss. This activity reviews liraglutide’s mechanism of action, dosing, pharmacodynamics, pharmacokinetics, adverse event profile, off-label uses, monitoring, and relevant interactions. These aspects of liraglutide are critical for healthcare professionals managing patients with T2D and related conditions. Understanding liraglutide’s proper indications and potential side effects supports effective communication across the interprofessional healthcare team.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 1.5 creditsAMA PRA Category 1 Credit™Up to 1.5 creditsNursingUp to 1.5 creditsPharmacyUp to 1.5 credits

MOC types

ABS — Accredited CMEUp to 1.5 pointsABPATH — Lifelong LearningUp to 1.5 pointsABA — Lifelong LearningUp to 1.5 pointsABTS — Accredited CMEUp to 1.5 pointsABIM — Medical KnowledgeUp to 1.5 pointsABS — Self-AssessmentUp to 1.5 pointsABP — Lifelong Learning and Self-AssessmentUp to 1.5 pointsABTS — Self-AssessmentUp to 1.5 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 9 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1.5 credits
  • MOC · Up to 1.5 points
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left